As we continue further into the multidrug resistant era, it becomes necessary to develop a deeper understanding of how to perform and interpret antimicrobial susceptibility testing. The clinical microbiology laboratory provides valuable susceptibility data that can...
PathCare introduces Xpert MTB/XDR testing as a reflex test for rapid molecular drug susceptibility testing of rifampicin-resistant Mycobacterium tuberculosis (RR-TB) positive clinical samples South Africa remains one of the top 30 high-burden countries for...
This report is a summary of the results obtained from various molecular respiratory panels performed across PathCare laboratories during July 2025 (epidemiological weeks 27-31). The data is dependent on submission of samples by clinicians and therefore may not be...
We are pleased to announce an important enhancement to our endocrine diagnostics service. As of 29 July 2025, our laboratory will transition from reporting urine total (deconjugated) metanephrines (currently performed via HPLC) to urine free (unconjugated)...
This report is a summary of the results obtained from various molecular respiratory panels performed across PathCare Laboratories during June 2025.Respiratory Pathogen Statistics June 2025
PathCare has developed a unique reporting tool which consolidates pathology results for diabetic patients. This report allows healthcare providers to assess diabetes management performance of their patient as a group, as well as at an individual level.The Diabetes...
Hyperkalaemia, defined as a potassium concentration greater than the reference interval, is a common electrolyte disorder that requires urgent attention. As both hyperkalaemia and hypokalaemia can have serious implications, it is imperative that the result obtained...
This report is a summary of the results obtained from various molecular respiratory panels performed across PathCare laboratories during May 2025.Respiratory Pathogen Statistics May 2025
Congenital cytomegalovirus (cCMV) infection carries a significant burden with a 0.64% global prevalence, while in resource-limited settings the prevalence may be in excess of 5%. New Guideline: Oral Valaciclovir for the prevention of congenital CVM
Laboratory-based data for all GIT molecular panels requested for patients at PathCare Laboratories nationally for January to April 2025 are presented in this report.The major pathogens detected from stool samples of patients investigated for diarrhoeal disease are...